Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 17/20 | 0.65 |
| ▸ | GGPS1 | O95749 | 8/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4097079 | 1.00 | FDPS (0.65) | FDPSGGPS1PDE3ALMNAADRB3 | |
| SCHEMBL9323797 | 0.98 | FDPS (0.64) | FDPSGGPS1PDE3ALMNAADRB3 | |
| SCHEMBL10705729 | 0.95 | FDPS (0.62) | FDPSGGPS1PDE3ALMNAADRB3 | |
| SCHEMBL9313278 | 0.90 | FDPS (0.77) | FDPSGGPS1PDE3ALMNAADRB3 | |
| SCHEMBL9313105 | 0.87 | FDPS (0.74) | FDPSGGPS1PDE3ALMNAADRB3 | |
| SCHEMBL15452862 | 0.87 | FDPS (0.76) | FDPSGGPS1PDE3ALMNAADRB3 | |
| SCHEMBL2461794 | 0.79 | FDPS (0.59) | FDPSGGPS1PDE3ALMNAADRB3 | |
| SCHEMBL6666352 | 0.79 | FDPS (0.63) | FDPSGGPS1PDE3ALMNAADRB3 | |
| SCHEMBL3287859 | 0.79 | FDPS (1.00) | FDPSGGPS1PDE3ALMNAADRB3 | |
| SCHEMBL6665992 | 0.79 | FDPS (1.00) | FDPSGGPS1PDE3ALMNAADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0141200-B1 | DIHYDROXYALKANEDIPHOSPHONIC ACIDS | Henkel Kommanditgesellschaft auf Aktien (DE) | 1988-07-27 | — | — | EP | claimed |
| US-4536348-A | OUTSTANDING COMPLEXING POWER | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1985-08-20 | — | — | US | claimed |
| EP-0141200-A2 | Dihydroxyalkanediphosphonic acids | Henkel Kommanditgesellschaft auf Aktien (DE) | 1985-05-15 | — | — | EP | claimed |
| US-8293029-B2 | Colored conversion layers on metal surfaces | HENKEL AG & CO. KGAA (DE) | 2012-10-23 | — | — | US | disclosed |
| WO-2011146819-A2 | METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES | DMD THERAPIES, LLC (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
| US-20090214883-A1 | CHROMIUM-FREE, THERMALLY CURABLE CORROSION PROTECTION COMPOSITION | HENKEL AG & CO. KGAA (DE) | 2009-08-27 | — | — | US | disclosed |
| EP-1658392-B1 | COLOUR CONVERSION LAYERS ON METAL SURFACES | HENKEL KGAA (DE) | 2007-03-14 | — | — | EP | disclosed |
| US-20060173099-A1 | Colored conversion layers on metal surfaces | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-08-03 | — | — | US | disclosed |
| EP-1188761-A1 | Novel geminal-diphosphonic acids and their manufacture | SOLVAY (Société Anonyme) (BE) | 2002-03-20 | — | — | EP | disclosed |
| US-5298221-A | Ferrous surfaces in contact with aqueous systems | W. R. GRACE & CO. - CONN. (US) | 1994-03-29 | — | — | US | disclosed |
| US-5221487-A | Water treatment | W. R. GRACE & CO.-CONN. (US) | 1993-06-22 | — | — | US | disclosed |
| EP-0141200-B1 | DIHYDROXYALKANEDIPHOSPHONIC ACIDS | Henkel Kommanditgesellschaft auf Aktien (DE) | 1988-07-27 | — | — | EP | disclosed |
| US-4536348-A | OUTSTANDING COMPLEXING POWER | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1985-08-20 | — | — | US | disclosed |
| EP-0141200-A2 | Dihydroxyalkanediphosphonic acids | Henkel Kommanditgesellschaft auf Aktien (DE) | 1985-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | FDPS 2668/4885GGPS1 2599/4885PDE3A 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.